A heart-to-heart conversation between Big Pharma and Big Fund managers included some pointed criticism of the industry's unproductive R&D operations and concerns about pressure from payers as well as patients for less expensive drugs. The managers are asking for more information on early-stage therapies, a plan for handling safety concerns without cutting back on development and a common sense approach to demonstrating the value of a drug to payers. The fund managers are also looking for a sales strategy that takes into account consumers who can afford to pay the full rate, at a discount or not at all.
- read the report [1] from The Wall Street Journal (sub. req.)
Related Articles:
PwC to pharma: Adapt and invest or die. Report [2]
Where's the ROI on drug R&D budgets? Report [3]
Is pharma's drug discovery model sustainable? Editorial [4]
Links:
[1] http://blogs.wsj.com/health/2007/06/19/big-pharma-disappoints-big-money/
[2] http://www.fiercebiotech.com/story/pwc-to-pharma-adapt-and-invest-or-die/2007-06-13
[3] http://www.fiercebiotech.com/story/where-s-the-roi-on-drug-rd-budgets/2006-12-20
[4] http://www.fiercebiotech.com/story/editor-s-corner/2006-08-14